Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.59 |
| ▸ | ESR1 | P03372 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8370024 | 1.00 | ESR2 (0.65) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL8370026 | 1.00 | ESR2 (0.65) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL1119887 | 0.95 | ESR2 (0.71) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL1531852 | 0.95 | ESR2 (0.71) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL9159105 | 0.91 | CYP2C9 (0.63) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL9159110 | 0.91 | CYP2C9 (0.63) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL9159091 | 0.91 | CYP2C9 (0.63) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL10893213 | 0.91 | CYP2C9 (0.63) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL10893211 | 0.91 | CYP2C9 (0.63) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 | |
| SCHEMBL10893199 | 0.91 | CYP2C9 (0.63) | ESR2CYP2C9ESR1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046889-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2021-06-29 | — | — | US | disclosed |
| US-10968189-B2 | Method for producing 2-hydrazinobenzothiazole derivative | DIC CORPORATION (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10927087-B2 | Method for producing polymerizable compound | DIC CORPORATION (JP) | 2021-02-23 | — | — | US | disclosed |
| US-10723952-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20200165215-A1 | METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE | DIC CORPORATION (JP) | 2020-05-28 | — | — | US | disclosed |
| US-10358602-B2 | Liquid crystal compound having polyfluoro-2-butenoxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-07-23 | — | — | US | disclosed |
| EP-3135659-B1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2018-12-19 | — | — | EP | disclosed |
| US-9951277-B2 | Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9951277-B2 | Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9896624-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| US-5196140-A | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-03-23 | — | — | US | disclosed |
| EP-0313604-B1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GmbH (DE) | 1992-03-25 | — | — | EP | disclosed |
| EP-0313604-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT. | MERCK PATENT GMBH (DE) | 1989-05-03 | — | — | EP | disclosed |
| EP-0205340-B1 | LIQUID CRYSTAL ESTER COMPOUND | Chisso Corporation (JP) | 1989-01-11 | — | — | EP | disclosed |
| WO-1988008441-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-11-03 | — | — | WO | disclosed |
| EP-0094487-B1 | HYDROTERPHENYLS, THEIR PREPARATION AND THEIR USE IN DIELECTRIC LIQUID CRYSTAL MATERIAL | MERCK PATENT GmbH (DE) | 1987-09-09 | — | — | EP | disclosed |
| US-4680137-A | Liquid crystal ester compound | CHISSO CORPORATION (JP) | 1987-07-14 | — | — | US | disclosed |
| EP-0205340-A1 | Liquid crystal ester compound | Chisso Corporation (JP) | 1986-12-17 | — | — | EP | disclosed |
| US-4620938-A | Hydroterphenyls | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-11-04 | — | — | US | disclosed |
| EP-0094487-A1 | Hydroterphenyls, their preparation and their use in dielectric liquid crystal material | MERCK PATENT GmbH (DE) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165215-A1 | METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE | HAO2, IDH2, HACL2 | ESR2 4274/4885CYP2C9 310/4885ESR1 4615/4885 |
| US-10927087-B2 | Method for producing polymerizable compound | INCENP, INF2, INHA | ESR2 4850/4885CYP2C9 885/4885ESR1 4825/4885 |
| US-11046889-B2 | Polymerizable compound and optically anisotropic body | OCIAD1, RCC1, OCIAD2 | ESR2 4015/4885CYP2C9 1735/4885ESR1 3310/4885 |
| US-10723952-B2 | Polymerizable compound and optically anisotropic body | SMC4, SMCHD1, PHOSPHO1 | ESR2 4827/4885CYP2C9 3871/4885ESR1 4289/4885 |
| US-10968189-B2 | Method for producing 2-hydrazinobenzothiazole derivative | HAO2, IDH2, HACL2 | ESR2 4274/4885CYP2C9 310/4885ESR1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.